Answer
It is licensed with amivantamab for adults receiving first-line treatment for advanced non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation.
Sources for this answer
- Lazcluze 80 mg film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.